These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36330944)

  • 21. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA.
    Tóth K; Wasserkort R; Sipos F; Kalmár A; Wichmann B; Leiszter K; Valcz G; Juhász M; Miheller P; Patai ÁV; Tulassay Z; Molnár B
    PLoS One; 2014; 9(12):e115415. PubMed ID: 25526039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Circulating Tumor DNA Methylation in Diagnosis of Colorectal Cancer.
    Xu F; Yu S; Han J; Zong M; Tan Q; Zeng X; Fan L
    Clin Transl Gastroenterol; 2021 Aug; 12(8):e00386. PubMed ID: 34382948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Clinical Significance of Septin 9 and Colon Cancer Specific Antigen-2 (CCSA-2) in Colorectal Cancer.
    Abd El Kader L; Soliman AH; Salem SE; Akel SY; Ibrahim NH
    Asian Pac J Cancer Prev; 2023 Mar; 24(3):1027-1036. PubMed ID: 36974558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylated septin 9 gene is an important prognostic marker in stage II and stage III colorectal cancer for evaluating local recurrence or distant metastasis after surgery.
    Huang M; He J; Lai W; Liu L; Xu H; Zeng Y; Lan Q; Lin X; Chu Z
    BMC Gastroenterol; 2022 Feb; 22(1):87. PubMed ID: 35227194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon.
    Lee HS; Hwang SM; Kim TS; Kim DW; Park DJ; Kang SB; Kim HH; Park KU
    Transl Oncol; 2013 Jun; 6(3):290-6. PubMed ID: 23730408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of Methylated SEPT9 in Korean Colorectal Cancer Patients: Comparison with Previous Studies.
    Kim H; Lee JK; Hong YJ; Moon SM; Shin US; Kwon H; Shin K; Chang YH
    Clin Lab; 2018 Sep; 64(9):1573-1579. PubMed ID: 30273999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma Methylated SEPT9 as a Novel Biomarker for Predicting Liver Metastasis in Colorectal Cancer.
    Yu M; Yang C; Wang S; Shi Y; Wang J; Meng C; Xue L; Chen Z
    Mol Biotechnol; 2023 Aug; ():. PubMed ID: 37608077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylated
    Hitchins MP; Vogelaar IP; Brennan K; Haraldsdottir S; Zhou N; Martin B; Alvarez R; Yuan X; Kim S; Guindi M; Hendifar AE; Kalady MF; DeVecchio J; Church JM; de la Chapelle A; Hampel H; Pearlman R; Christensen M; Snyder C; Lanspa SJ; Haile RW; Lynch HT
    BMJ Open Gastroenterol; 2019; 6(1):e000299. PubMed ID: 31275589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer.
    Song L; Guo S; Wang J; Peng X; Jia J; Gong Y; Yang B; Xiao W; Dong C; Liu H; Li Y
    Biomark Med; 2018 Sep; 12(9):961-973. PubMed ID: 30043648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients.
    Jiang H; Yu Q; Chen X; Zhang C; Shen J; Shen M; Yang Y; Wang B; Pan B; Guo W
    J Clin Lab Anal; 2021 Nov; 35(11):e24030. PubMed ID: 34591323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The quantitative profiling of blood mSEPT9 determines the detection performance on colorectal tumors.
    Song L; Wang J; Wang H; Chen Y; Jia J; Guo S; Liu H; Peng X; Xiao W; Gong Y; Yang B; Lu Y; Li Y
    Epigenomics; 2018 Dec; 10(12):1569-1583. PubMed ID: 30426784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Value of plasma SEPTIN9 methylation detection for diagnosis and predicting radiosensitivity of esophageal carcinoma].
    Sun Q; Liu J; Fan X; Zhou Y; Wang X; Cui Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(8):1214-1219. PubMed ID: 34549713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression and clinical significance of plasma methylated SEPT 9 gene in patients with primary liver cancer].
    He N; Feng G; Zhang FN; Hao S; Li R; Zhao ZQ; Tian YW; Yan HL
    Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):265-270. PubMed ID: 37137852
    [No Abstract]   [Full Text] [Related]  

  • 34. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical value of combining serum tumor marker detection with fecal occult blood testing in diagnosing colorectal cancer.
    Zhou H; Wang XC; Yuan BB; Lu BB
    J Physiol Pharmacol; 2022 Jun; 73(3):. PubMed ID: 36515627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of the methylated SEPT9 test for the early detection of colorectal cancer: a systematic review and meta-analysis of diagnostic test accuracy.
    Hariharan R; Jenkins M
    BMJ Open Gastroenterol; 2020; 7(1):e000355. PubMed ID: 32128229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis.
    Song L; Yu H; Jia J; Li Y
    Cancer Biomark; 2017; 18(4):425-432. PubMed ID: 28128742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer.
    Qi J; Qian C; Shi W; Wu X; Jing R; Zhang L; Wang Z; Ju S
    Clin Biochem; 2013 Jan; 46(1-2):64-9. PubMed ID: 22975639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual-modality loop-mediated isothermal amplification for pretreatment-free detection of Septin9 methylated DNA in colorectal cancer.
    Lin Q; Fang X; Chen H; Weng W; Liu B; Kong J
    Mikrochim Acta; 2021 Aug; 188(9):307. PubMed ID: 34453211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
    Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
    J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.